Anime arena fighters have been in an awkward slump for years thanks in significant part to the monumental gap left by Dragon ...
Data from the HERCULES trial presented at the ECTRIMS conference in Copenhagen, Denmark, today showed that tolebrutinib was ...
This year's newbies range from a 400-footer that charters for $3.25 million per week to multiple hybrid yachts, including one ...
The Department of National Defence has announced it's implementing a new technology that uses cell phones to find people ...
What-If stories and Dragon Ball have gone hand-in-hand since Dragon Ball Z: Super ButÅden 2 for the SNES in 1993. The fandom ...
Agatha Christie’s classic is adapted for a new stage tour, currently playing at the Lowry in Salford ...
The Royal Canadian Air Force and Civil Air Search and Rescue Association have launched the Cellular Airborne Sensors for ...
The HERCULES study of tolebrutinib is the first and only to show reduced confirmed disability progression at 6 months in non-relapsing secondary progressive multiple sclerosis.
Tolebrutinid significantly delayed confirmed disability progression in people with nonrelapsing SPMS over a placebo in a ...
In this article, we take a look at six biotech companies focused on bringing drugs to treat obesity to the market.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback